BEOVU J Code: J0179
Injection, brolucizumab-dbll, 1 mg
Q4 2026 Medicare Payment Limit for J0179, effective October 1, 2026: $360.439 per HCPCS billing unit, up 0.2% from $359.713. From CMS's final file.
Drug & Product Overview
About BEOVU
Beovu is a medication aligned to the HCPCS J Code: J0179 for billing, pricing, and reimbursement purposes in the United States. Classified under Ophthalmology, it is administered via the intravitreal route and manufactured by Novartis.
According to CMS Drug Use Information: Brolucizumab is used to treat certain serious eye conditions (wet age-related macular degeneration, diabetic macular edema). This medication can help preserve vision and prevent blindness. Brolucizumab belongs to a class of drugs known as growth factor inhibitors. It works by slowing the growth of abnormal new blood vessels in the eye and decreasing leakage from these blood vessels.
Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.
NDC Code Information
Based on publicly available CMS files. The list of NDCs below is not exhaustive.
| NDC Code | Drug | Manufacturer | Billing Units / Pkg | Package Size |
|---|---|---|---|---|
| 00078-0827-60 | Beovu | Novartis Pharmaceuticals Corporation | 6 | 6 MG / 0.05 ML |
BEOVU Pricing & Reimbursement
National median reimbursement across major commercial payers.
Create an account on PayerPrice for more information →Historical Graphing and Billing Calculator
Log in to calculate billing and reimbursement with live ASP, WAC & AWP pricing.
Login to use the calculator →BEOVU CPT Administration Codes
The below list of CPT codes is intended for informational purposes only and may not be exhaustive. CPT® codes and descriptions are copyright American Medical Association (AMA). All rights reserved.
| CPT Code | Description |
|---|---|
| 67028 | Intravitreal injection of a pharmacologic agent (separate procedure) 67028 |
CMS has identified Beovu (J0179) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. Wastage billing guide →
BEOVU Medically Unlikely Edits (MUE)
The most billing units of J0179 Medicare will pay for one patient in one day, as published by CMS. 1 unit = 1 mg.
MAI 2 · Date of Service Edit: Policy. Absolute per-day limit set by policy or regulation; units above it are not payable, and denials are not appealable on medical-necessity grounds. See all MUE limits →
BEOVU Clinical Information
Indications and drug classification.
This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.
Login for BuyandBill.com Analytics
Unlock deeper insights with BuyandBill’s Comparative Report!
- Compare ASP, WAC, and AWP across drugs.
- Visualize Drug Price Movement Over Time
- Tailor reports to drug class, manufacturer, or HCPCS Code.
- Compare Biosimilar and 505(b)(2) products.
Frequently Asked Questions
Is there an available Beovu billing and coding guide?
Are there any available Beovu patient assistance programs?
Where can I find Beovu prescribing information?
Where can I find Beovu side effect information?
Does billing BEOVU require JZ/JW wastage modifiers?
About BuyandBill.com:
The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.
Related Drug Codes
Explore billing, coding, and pricing for drugs related to BEOVU.